Samsung Bioepis To Initiate Phase 1 Trial Of SB26 Ulinastatin-Fc Fusion Protein


(RTTNews.com) - Samsung Bioepis Co., Ltd. said it will soon begin a Phase 1 study to evaluate SB26 in healthy volunteers. SB26, also known as TAK-671, is a ulinastatin-Fc (UTI-Fc) fusion protein intended to treat severe acute pancreatitis. Non-clinical GLP safety studies performed in monkeys and rats supported early human studies with SB26.

The randomized, double-blind, placebo-controlled, single and multiple dose escalation Phase 1 study is designed to assess the safety, tolerability and pharmacokinetics of intravenous SB26 in healthy volunteers. Results of the Phase 1 study are expected in the third quarter of 2020.

SB26 is the first therapeutic candidate in the risk-sharing strategic collaboration agreement between Samsung Bioepis and Takeda Pharmaceutical Company Limited , which brings together Samsung Bioepis' agile biologics development platform with Takeda's best-in-class experts in drug development to co-fund and collaboratively develop innovative therapies representing meaningful value to patients who need them.


Read the original article on RTTNews (http://www.rttnews.com/2925869/samsung-bioepis-to-initiate-phase-1-trial-of-sb26-ulinastatin-fc-fusion-protein.aspx)


For comments and feedback: contact editorial@rttnews.com




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.